Pharmaceuticals, Biotechnology & Life Sciences

UniQure insider buys signal optimism: execs purchase tens of thousands of shares and options, boosting confidence in gene‑therapy milestones.

LO Francis’s March 5 sell‑to‑cover shows no market shift—just tax‑withholding. Stable insider trades, earnings optimism, and a strong diagnostics edge keep ADPT’s future looking bright.

CEO Marc N. Casper buys Thermo Fisher shares at a discount while selling high‑volume 10(b) 5‑1 plans, showing confidence in the company’s growth and a disciplined liquidity strategy.

Insider buying fuels optimism for Agenus’s TCR therapy and bispecific platform, highlighting potential growth amid FDA milestones and partnership upside.

Crystal Adam’s March 2026 sale of 20,251 Tango shares is a routine Rule 10b‑5 move amid strong trial data and a new Erasca partnership—no red flags yet.

Jack Zhang’s March 2026 sale of 5,769 Amphastar shares suggests routine RSU tax‑planning, not a confidence warning—investors should monitor pipeline milestones and insider trends for clearer signals.

Amphastar insider sales reveal routine tax‑planning, not a shift in confidence, amid tech upgrades and reimbursement changes that shape its future value.

Apogee Therapeutics insider trades reveal CMO confidence in Phase 2 milestones, fast‑track ADC pipeline, and value‑based commercialization strategy.

Insider buying at Adaptive Biotechnologies signals management confidence, aligning incentives and suggesting disciplined capital use amid AI‑driven diagnostics growth.

Lineage Cell Therapeutics’ latest insider activity shows CEO Brian Culley and senior execs aligning long‑term incentives with shareholder value as the company pushes cell‑therapy milestones, tackles regulatory & reimbursement hurdles, and leverages …